Affimed (NASDAQ:AFMD) Given Consensus Rating of “Buy” by Analysts

Affimed (NASDAQ:AFMD) has been assigned a consensus recommendation of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $45.00.

AFMD has been the subject of a number of research reports. HC Wainwright lifted their price objective on Affimed to $10.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Monday, April 1st. StockNews.com initiated coverage on Affimed in a research note on Tuesday, January 2nd. They issued a “sell” rating for the company. Finally, Wells Fargo & Company dropped their price objective on Affimed from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, April 1st.

Affimed Trading Down 4.5 %

Shares of NASDAQ AFMD opened at $5.49 on Thursday. Affimed has a twelve month low of $2.23 and a twelve month high of $11.10. The company has a current ratio of 3.25, a quick ratio of 3.23 and a debt-to-equity ratio of 0.11. The stock has a fifty day simple moving average of $5.56 and a 200-day simple moving average of $5.00. The stock has a market capitalization of $83.60 million, a PE ratio of -0.65 and a beta of 2.05.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vestal Point Capital LP acquired a new position in Affimed during the 4th quarter worth $341,000. BNP Paribas Financial Markets grew its stake in Affimed by 39.9% during the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after purchasing an additional 163,162 shares in the last quarter. EWA LLC acquired a new position in shares of Affimed during the 4th quarter worth about $89,000. abrdn plc acquired a new position in shares of Affimed during the 4th quarter worth about $130,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Affimed during the 2nd quarter worth about $129,000. 30.82% of the stock is owned by institutional investors and hedge funds.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.